Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 449 participants.
Also called NCT01928628
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 449 participants
- Sponsor
- Registry
-
NCT01928628
-
- Other papers using this trial's data
- Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- Not reported
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01928628. Randomized; double masking; primary purpose treatment. Start 2012-05 (registry gives no type); primary completion 2013-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients
- Condition
- Hypertension
- Intervention (Drug)
- Lercanidipine 10mg
- Intervention (Drug)
- Lercanidipine10mg /Valsartan 80mg
- Intervention (Drug)
- Lercanidipine 10mg /Valsartan 160mg
- Intervention (Drug)
- Lercanidipin 10mg Placebo
- Intervention (Drug)
- Lercanidipine10mg /Valsartan 80mg Placebo
- Intervention (Drug)
- Lercanidipine 10mg /Valsartan 160mg Placebo
- Lead sponsor
- LG Life Sciences
Record details
- Record id
cardio:ct-nct01928628- Content hash
ea5167166f9db68a157fa4db4ca838530c93218ff330b0ca33725dcfe88fee4e